Home / Business News (page 5)

Business News

Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics

NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), and Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, …

Read More »

Amgen Wins Enbrel US Patent Litigation, Delaying Sandoz’s Biosimilar Plan

THOUSAND OAKS, Calif., Aug. 9, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen’s favor on validity of the two patents that describe and claim Enbrel® (etanercept) and methods for making it. Amgen affiliates Immunex Corporation and Amgen Manufacturing, Limited, along with the owner and licensor of the two patents, Hoffmann-La …

Read More »

Siemens to Acquire Corindus Vascular Robotics for $1.1 Billion

WALTHAM, Mass., — August 8, 2019 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens …

Read More »

Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ — Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may be able to differentiate …

Read More »

Bayer to Acquire BlueRock Therapeutics to Build Leading Position in Cell Therapy

BERLIN and CAMBRIDGE, Mass., Aug. 8, 2019 /PRNewswire/ — Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced …

Read More »

NORD and C-Path to Launch FDA-Funded Rare Disease Data Analytics Platform

TUCSON, Ariz. and WASHINGTON, Aug. 7, 2019 /PRNewswire/ — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders® (NORD) will host a meeting on Tuesday, September 17 in Bethesda, MD to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative …

Read More »

Novartis Responds to FDA Statement on Data Accuracy Issues with its Recently Approved Gene Therapy Zolgensma

Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients …

Read More »

Takeda and Sosei Heptares Enter Partnership to Develop Small Molecules and Biologics that Modulate GPCR Targets

TOKYO and LONDON, Aug. 5, 2019 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces that it has entered into a strategic multi-target partnership with Takeda Pharmaceutical Company Limited (“Takeda”)1, to discover, develop and commercialize novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (“GPCR”) targets. …

Read More »

Phase 3 Trial of Transgene’s Pexa-Vec Liver Cancer Halted Early Following Planned Interim Futility Analysis

Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, today announces that the independent Data Monitoring Committee (“IDMC”) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis. Sillajen has informed Transgene of the IDMC’s recommendation to …

Read More »

Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology

TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) and AVEO Oncology (NASDAQ: AVEO) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU. The agreement is an …

Read More »